American Society of Clinical Oncology Gastrointestinal (ASCO GI) Symposium

In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.

ASCO GI 2020

No Local Control or OS Benefit Seen With RT Dose Escalation in Inoperable Esophageal Cancer

January 22, 2020

In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.

Results from the international, noninferiority phase 3 TARGIT-A trial continue to be questioned by r

ASCO GI 2020

The 2020 Gastrointestinal Cancers Symposium: What to Expect

Cancer Therapy Advisor Staff

January 17, 2020

Cancer Therapy Advisor’s coverage of the Gastrointestinal Cancers Symposium will reflect the theme of personalized care across multiple types of gastrointestinal cancers.

Next post in ASCO GI 2020

American Society of Clinical Oncology Gastrointestinal (ASCO GI) Symposium

No Local Control or OS Benefit Seen With RT Dose Escalation in Inoperable Esophageal Cancer

The 2020 Gastrointestinal Cancers Symposium: What to Expect

Want to read more?

Longer Maintenance of QoL in BRAF V600E-Mutant Metastatic Colorectal Cancer With Triplet Regimen vs an Irinotecan-Based Regimen